首页> Journal of translational medicine> 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor.

3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor.

导出 OA

翻译打印收藏纠错

第一作者： James L,Tatum

第一单位： Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

作者： James L,Tatum ^[1] ; Joseph D,Kalen ^[2] ; Paula M,Jacobs ^[3] ; Lisa A,Riffle ^[2] ; Amy,James ^[4] ; Lai,Thang ^[4] ; Chelsea,Sanders ^[4] ; Melinda G,Hollingshead ^[5] ; Falguni,Basuli ^[6] ; Jianfeng,Shi ^[6] ; James H,Doroshow ^[1]

作者单位： Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States. ^[1] Small Animal Imaging Program, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, United States. ^[2] Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States. jacobsp@mail.nih.gov. ^[3] Animal Research Technical Support, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, United States. ^[4] Biological Testing Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Frederick, MD, United States. ^[5] Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States. ^[6]

关键词 CDK4/6 FLT PET Imaging biomarkers Palbociclib Response biomarker